Video Series: Current Topics in the Treatment of Advanced PCa

Targeted Agents

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Latest Prostate Cancer Features

Latest Prostate Cancer News

Fewer Early PCa Diagnoses Following USPSTF Recs

Fewer Early PCa Diagnoses Following USPSTF Recs

Early prostate cancer diagnosis rates fell, while cases of advanced prostate cancer remained stable.

Treatment Regret Infrequent After Radical Prostatectomy, IMRT

Treatment Regret Infrequent After Radical Prostatectomy, IMRT

Overall decision regret for 16.9% of patients; more regret for RP than radiotherapy component.

Radium-223 With Concomitant Therapy May Prolong Life With mCRPC

Radium-223 With Concomitant Therapy May Prolong Life With mCRPC

Survival was longer in patients who received radium-223 plus abiraterone, enzalutamide, or both.

High-Grade Prostate Cancer Linked to Diabetes Drugs

High-Grade Prostate Cancer Linked to Diabetes Drugs

Men who used the medications prior to radical prostatectomy had 83% greater odds of Gleason 7-10 tumors compared with non-users.

Radical Local Therapy Offers Mortality Benefit in Very High-Risk PCa

Radical Local Therapy Offers Mortality Benefit in Very High-Risk PCa

Prostatectomy and radiotherapy with or without ADT reduced prostate cancer-specific and all-cause mortality rates.

Adjuvant ADT May Up Mortality in Black Prostate Cancer Patients

Adjuvant ADT May Up Mortality in Black Prostate Cancer Patients

Androgen deprivation increased all-cause mortality risk by 77% among black men who underwent brachytherapy for favorable-risk prostate cancer.

Selenium May Cut Aggressive Prostate Cancer Risk

Selenium May Cut Aggressive Prostate Cancer Risk

An analysis of individual participant data from 15 prospective studies suggests a protective effect.

ED Drugs May Not Reduce Prostate Cancer Risk

ED Drugs May Not Reduce Prostate Cancer Risk

Prostate cancer was diagnosed in 19.5% of PDE5i users vs 22.7% of nonusers, a statistically insignificant difference.

Skeletal-Related Events Predict Higher Mortality in mCRPC

Skeletal-Related Events Predict Higher Mortality in mCRPC

Skeletal-related events occurred in 38% of patients with metastatic castration-resistant prostate cancer.

Intestinal Autoimmunity Possibly Linked to ADT

Intestinal Autoimmunity Possibly Linked to ADT

ADT for prostate cancer may be associated with a reduced risk of inflammatory bowel disease.

Identity Factors Influence Prostate Cancer Treatment Method

Identity Factors Influence Prostate Cancer Treatment Method

Ethnicity, education identified as factors that influence patients treatment decisions.

Obesity Common in Cancer Survivors

Obesity Common in Cancer Survivors

Prevalence of obesity is high in adults with a history of breast, prostate, or colorectal cancer.

Survival Outcomes in Gleason 9-10 PCa Similar With Radiation, Surgery

Survival Outcomes in Gleason 9-10 PCa Similar With Radiation, Surgery

External beam radiation therapy (EBRT) plus brachytherapy found to offer improved systemic control versus EBRT alone and radical prostatectomy.

Robotic, Open Prostate Cancer Surgery Offer Similar Early Results

Robotic, Open Prostate Cancer Surgery Offer Similar Early Results

No significant differences observed in standard oncologic outcomes and quality of life at 12 weeks.

Race Affects Switch From Prostate Cancer Observation to Active Therapy

Race Affects Switch From Prostate Cancer Observation to Active Therapy

Blacks found to be slightly more likely than whites to leave observational management to undergo radiotherapy or surgery.

Prostate Cancer Videos

Sign up for free e-Newsletters